N-(3-(Phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: Structure, synthesis and SAR

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1172-1176

  Deak, Holly L ^a   Newcomb, John R ^a   Nunes, Joseph J ^a   Boucher, Christina ^a   Cheng, Alan C ^a   DiMauro, Erin F ^a   Epstein, Linda F ^a   Gallant, Paul ^a   Hodous, Brian L ^a   Huang, Xin ^a   Lee, Josie H ^a   Patel, Vinod F ^a   Schneider, Stephen ^a   Turci, Susan M ^a   Zhu, Xiaotian ^a  

^a AMGEN INC   (United States)

Author keywords

Kinase inhibitor; Lck inhibitor

Indexed keywords

AMIDE; LCK KINASE INHIBITOR; N [3 (PHENYLCARBAMOYL)ARYLPYRIMIDINE] 5 CARBOXAMIDE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE LCK; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

AMIDES; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; HYDROGEN BONDING; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THREONINE;

PYRONIA TITHONUS;

EID: 38749084544     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.123     Document Type: Article

References (24)

1. Marth J.D., Lewis D.B., Cooke M.P., Mellins E.D., Gearn M.E., Samelson L.E., Wilson C.B., Miller A.D., and Perlmutter R.M. J. Immunol. 142 (1989) 2430
2. Groves T., Smiley P., Cooke M.P., Forbush K., Perlmutter R.M., and Guidos C.J. Immunity 5 (1996) 417
3. Palacios E.H., and Weiss A. Oncogene 23 (2004) 7990
4. Molina T.J., Kishihara K., Siderovskid D.P., van Ewijk W., Narendran A., Timms E., Wakeham A., Paige C.J., Hartmann K.-U., Veillette A., Davidson D., and Mak T.W. Nature 357 (1992) 161
5. Straus D.B., and Weiss A. Cell 70 (1992) 585
6. Levin S.D., Anderson S.J., Forbush K.A., and Perlmutter R.M. EMBO J. 12 (1993) 1671
7. Goldman F.D., Ballas Z.K., Schutte B.C., Kemp J., Hollenback C., Noraz N., and Taylor N. J. Clin. Invest. 102 (1998) 421
8. Hubert P., Bergeron F., Ferreira V., Seligmann M., Oksenhendler E., Debre P., and Autran B. Int. Immunol. 12 (2000) 449
9. Seddon B., and Zamoyska R. J. Immunol. 169 (2002) 2997
10. Snow R.J., Cardozo M.G., Morwick T.M., Busacca C.A., Dong Y., Eckner R.J., Jacober S., Jakes S., Kapadia S., Lukas S., Panzenbeck M., Peet G.W., Peterson J.D., Prokopowicz III A.S., Sellati R., Tolbert R.M., Tschantz M.A., and Moss N. J. Med. Chem. 45 (2002) 3394
11. Das J., Lin J., Moquin R.V., Shen Z., Spergel S.H., Wityak J., Doweyko A.M., DeFex H.F., Fang Q., Pang S., Pitt S., Shen D.R., Schieven G.L., and Barrish J.C. Bioorg. Med. Chem. Lett. 13 (2003) 2145
12. Burchat A., Borhani D.W., Calderwood D.J., Hirst G.C., Li B., and Stachlewitz R.F. Bioorg. Med. Chem. Lett. 16 (2006) 118
13. Chen P., Doweyko A.M., Norris D., Gu H.H., Spergel S.H., Das J., Moquin R.V., Lin J., Wityak J., Iwanowicz E.J., McIntyre K.W., Shuster D.J., Behnia K., Chong S., de Fex H., Pang S., Pitt S., Shen D.R., Thrall S., Stanley P., Kocy O.R., Witmer M.R., Kanner S.B., Schieven G.L., and Barrish J.C. J. Med. Chem. 47 (2004) 4517
14. Martin M.W., Newcomb J., Nunes J.J., McGowan D.C., Armistead D.M., Boucher C., Buchanan J.L., Buckner W., Chai L., Elbaum D., Epstein L.F., Faust T., Flynn S., Gallant P., Gore A., Gu Y., Hsieh F., Huang X., Lee J.H., Metz D., Middleton S., Mohn D., Morgenstern K., Morrison M.J., Novak P.M., Oliveira-dos-Santos A., Powers D., Rose P., Schneider S., Sell S., Tudor Y., Turci S.M., Welcher A., White R.D., Zack D., Zhao H., Zhu L., Zhu X., Ghiron C., Amouzegh P., Ermann M., Jenkins J., Johnston D., Napier S., and Power E. J. Med. Chem. 49 (2006) 4981
15. DiMauro E.F., Newcomb J., Nunes J.J., Bemis J.E., Boucher C., Buchanan J.L., Buckner W.H., Cee V.J., Chai L., Deak H.L., Epstein L.F., Faust T., Gallant P., Geuns-Meyer S.D., Gore A., Gu Y., Henkle B., Hodous B.L., Hsieh F., Huang X., Kim J.L., Lee J.H., Martin M.W., Masse C.E., McGowan D.C., Metz D., Mohn D., Morgenstern K.A., Oliveira-dos-Santos A., Patel V.F., Powers D., Rose P.E., Schneider S., Tomlinson S.A., Tudor Y.-Y., Turci S.M., Welcher A.A., White R.D., Zhao H., Zhu L., and Zhu X. J. Med. Chem. 49 (2006) 5671
16. Liu Y., and Gray N.S. Nat. Chem. Biol. 2 (2006) 358 and references therein
17. For descriptions of assays, including the human mixed lymphocyte reaction, please see Ref. 3e.
18. Fraley M.A., Hoffman W.F., Arrington K.L., Hungate R.W., Hartman G.D., McFall R.C., Coll K.E., Rickert K., Thomas K.A., and McGaughey G.B. Curr. Med. Chem. 11 (2004) 709
19. Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., and Rowsell S. Bioorg. Med. Chem. Lett. 16 (2006) 1320
20. ++·ATP for 10 min at room temperature. Phosphorylated Lck was further purified by anion exchange chromatography and concentrated to 10 mg/mL. The coordinates for the X-ray co-crystal structure of Lck and 11 have been deposited in the PDB. The RCSB ID code is RCSB045010 and the PDB ID code is 3B2W.
21. For examples, see:. Tamayo N., Liao L., Goldberg M., Powers D., Tudor Y.-Y., Yu V., Wong L.M., Henkle B., Middleton S., Syed R., Harvey T., Jang G., Hungate R., and Dominguez C. Bioorg. Med. Chem. Lett. 15 (2005) 2409
22. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., and Regan J. Nat. Struct. Biol. 9 (2002) 268
23. 1H NMR and LC/MS and their purity determined to be >95% by reverse phase HPLC.
24. Luecking, U.; Siemeister, G.; Schaefer, M.; Briem, H. Ger. Offen. DE 10239042, 2004.